News | March 01, 2023
AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Twelve hospitals across India will be part of the network which will support the trial in India
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Clinical studies are expected to start in Q2 2023.
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Subscribe To Our Newsletter & Stay Updated
